10/15/2010

Disclosure Under Chapter 2 Section 9

ORION CORPORATION STOCK EXCHANGE RELEASE  15 October  2010  AT 5.45  PM EET

 

Orion Corporation (business code 1999212-6) has received a disclosure under Chapter 2, Section 9 of the Securities Markets Act, according to which the total number of Orion B shares owned by the mutual funds under  the management of Capital Research and Management Company, has on 13 October 2010 through trades in the course of ordinary business fallen below one twentieth (1/20) of  the total number of Orion Corporation shares.

The holding of the mutual funds under  the management of Capital Research and Management Company's according to the disclosure:

Share type Number of shares Percent (%) of
total shares
Percent (%)
voting rights
A share 0 0 0
B share
ISIN:FI0009014377
6,979,085 4.9407 0.6640
Total 6,979,085 4.9407 0.6640

 

The taxpayer I.D. advised by Capital Research and Management Company: 95-1411037. Additional information about the company: www.capgroup.com.

Orion Corporation's share capital comprises 141,257,828 shares, of which 47,885,511 are A shares and 93,372,317 are B shares. Each A share entitles its holder to twenty (20) votes and each B share to one (1) vote. Thus, the total number of votes is 1,051,082,537.

 

                                                                                                                                 
Orion Corporation

 

 

 

Timo Lappalainen                       Olli Huotari
President and CEO                    SVP, Corporate Functions

 

 

Contact person:
Olli Huotari, SVP, Corporate Functions, phone +358 50 966 3054

 

 

 

 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi

 

 

Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.

 

The Group's net sales in 2009 amounted to EUR 772 million. The Company invested EUR 95 million in research and development. At the end of 2009, the Group had a total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.